<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7207128\results\search\testTrace\results.xml">
  <result pre="the COVID-19 resource centre remains active. Abstract The new coronavirus" exact="infection" post="COVID-19 has quickly become a global health emergency. Mortality"/>
  <result pre="socio-economic crisis. This rises the need to urgently find a" exact="treatment" post="in order to reduce the length of stay in"/>
  <result pre="only supportive [3]. But there are many ongoing clinical trials" exact="testing" post="potential antiviral drugs that have been used against Betacoronaviruses"/>
  <result pre="and a severe hypercytokinaemia [6]. The revised criteria for HLH" exact="diagnosis" post="include fever, splenomegaly, bicytopenia, hypertriglyceridaemia or hypofibrinogenaemia (or both),"/>
  <result pre="the eight criteria in total are needed to make a" exact="diagnosis" post="of HLH (Table 1 ) [7]. It is noteworthy"/>
  <result pre="The latter cells may be haemophagocytes. Table 1 Secondary HLH" exact="diagnosis" post="criteria. 1. Fever 2. Splenomegaly 3. Cytopenias (affecting â‰¥2"/>
  <result pre="Soluble CD25 (i.e., soluble IL-2 receptor) â‰¥2400 U/ml Secondary HLH" exact="diagnosis" post="criteria adapted from Henter et al. 2007. Five out"/>
  <result pre="fulfilled. Even though the pathophysiology of HLH secondary to an" exact="infection" post="is still largely unclear, it is presumably similar to"/>
  <result pre="observations made in the context of HLH development during H1N1" exact="infection" post="[13]. Hence, there are accumulating elements suggesting that moderately"/>
  <result pre="severe COVID-19 might be a form of sHLH. Could sHLH" exact="treatment" post="be applied on COVID-19? Etoposide-based treatment is the standard"/>
  <result pre="of sHLH. Could sHLH treatment be applied on COVID-19? Etoposide-based" exact="treatment" post="is the standard of care for sHLH following the"/>
  <result pre="by the HLH Steering Committee of the Histiocyte Society. The" exact="treatment" post="aims at dampening the cytokine storm and is based"/>
  <result pre="case of central nervous system involvement [14], [15]. Interestingly, this" exact="treatment" post="induced complete remissions in moderately severe to severe sHLH"/>
  <result pre="especially when it was started less than 4Â weeks from" exact="infection" post="diagnosis [16], [17], [18]. The combination has also been"/>
  <result pre="when it was started less than 4Â weeks from infection" exact="diagnosis" post="[16], [17], [18]. The combination has also been reported"/>
  <result pre="of COVID-19. It would be possible also to propose this" exact="treatment" post="to COVID-19 patients who are already suffering from a"/>
  <result pre="with EBV associated HLH [16], [17], [18]. How could the" exact="treatment" post="be tested? The HLH Steering Committee of the Histiocyte"/>
  <result pre="a week with weekly decisions on whether to continue etoposide" exact="treatment" post="or not, following the clinical and laboratory response of"/>
  <result pre="studyLancet Respir Med2020 3WHO. Clinical management of severe acute respiratory" exact="infection" post="when novel coronavirus (nCoV) infection is suspected. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected; 2020."/>
  <result pre="management of severe acute respiratory infection when novel coronavirus (nCoV)" exact="infection" post="is suspected. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected; 2020. 4HuangC.WangY.LiX.Clinical features of patients infected"/>
  <result pre="8FardetL.GalicierL.LambotteO.Development and validation of the HScore, a score for the" exact="diagnosis" post="of reactive hemophagocytic syndromeArthritis Rheumatol6620142613262024782338 9RuanQ.YangK.WangW.JiangL.SongJ.Clinical predictors of mortality"/>
  <result pre="use of etoposide-based therapy and bone marrow transplantation for the" exact="treatment" post="of HLH: consensus statements by the HLH steering committee"/>
  <result pre="HLH study centerMed Pediatr Oncol41200310310912825212 18ImashukuS.KuriyamaK.TeramuraT.Requirement for etoposide in the" exact="treatment" post="of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosisJ Clin Oncol1920012665267311352958 19HenterJ.I.Palmkvist-KaijserK.HolzgraefeB.BrycesonY.T.PalmerK.Cytotoxic therapy"/>
  <result pre="swine flu A/H1N1Lancet3762010211621168053 20AleemA.Al AmoudiS.Al-MashhadaniS.SiddiquiN.Haemophagocytic syndrome associated with hepatitis-B virus" exact="infection" post="responding to etoposideClin Lab Haematol27200539539816307542 21TrottestamH.HorneA.AricoM.Chemoimmunotherapy for hemophagocytic lymphohistiocytosis:"/>
  <result pre="Haematol27200539539816307542 21TrottestamH.HorneA.AricoM.Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94" exact="treatment" post="protocolBlood11820114577458421900192 22JohnsonT.S.TerrellC.E.MillenS.H.KatzJ.D.HildemanD.A.JordanM.B.Etoposide selectively ablates activated T cells to control"/>
 </snippets>
</snippetsTree>
